Envista Holdings Co. (NYSE:NVST – Get Free Report) has been given an average rating of “Hold” by the fifteen analysts that are presently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $19.63.
NVST has been the topic of several analyst reports. Piper Sandler dropped their price target on shares of Envista from $18.00 to $16.00 and set a “neutral” rating on the stock in a research note on Tuesday, July 30th. Robert W. Baird dropped their price target on shares of Envista from $19.00 to $17.00 and set a “neutral” rating on the stock in a research note on Monday, July 22nd. Wells Fargo & Company assumed coverage on shares of Envista in a report on Tuesday, October 8th. They set an “equal weight” rating and a $20.00 price objective for the company. JPMorgan Chase & Co. lowered shares of Envista from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $23.00 to $16.00 in a report on Thursday, August 8th. Finally, Evercore ISI raised their price objective on shares of Envista from $18.00 to $23.00 and gave the stock an “outperform” rating in a report on Monday, September 23rd.
Get Our Latest Research Report on NVST
Insider Activity
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of NVST. GAMMA Investing LLC boosted its stake in Envista by 69.8% during the 3rd quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock valued at $35,000 after purchasing an additional 726 shares during the period. Blue Trust Inc. boosted its stake in Envista by 69.7% during the 3rd quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock valued at $39,000 after purchasing an additional 804 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in Envista by 50.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock valued at $43,000 after purchasing an additional 728 shares during the period. Versant Capital Management Inc boosted its stake in Envista by 1,420.3% during the 2nd quarter. Versant Capital Management Inc now owns 3,147 shares of the company’s stock valued at $52,000 after purchasing an additional 2,940 shares during the period. Finally, Innealta Capital LLC bought a new stake in shares of Envista during the 2nd quarter worth about $78,000.
Envista Stock Performance
Shares of NVST stock opened at $18.66 on Wednesday. Envista has a 52 week low of $15.15 and a 52 week high of $25.64. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.22 and a quick ratio of 1.90. The company’s fifty day simple moving average is $18.40 and its 200-day simple moving average is $18.08.
Envista (NYSE:NVST – Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.27 by ($0.16). Envista had a positive return on equity of 4.86% and a negative net margin of 52.25%. The firm had revenue of $633.10 million for the quarter, compared to analysts’ expectations of $646.88 million. During the same period last year, the firm earned $0.43 EPS. The business’s quarterly revenue was down 4.4% on a year-over-year basis. On average, equities research analysts expect that Envista will post 0.69 earnings per share for the current year.
About Envista
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Further Reading
- Five stocks we like better than Envista
- 3 REITs to Buy and Hold for the Long Term
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- How to Capture the Benefits of Dividend Increases
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Stock Splits, Do They Really Impact Investors?
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.